DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)

Conditions

In Stent Restenosis

Brief summary

Data regarding the usefulness of percutaneous coronary intervention (PCI) with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR) in every day clinical practice is scarce. We aimed to evaluate comparing the efficacy and safety profile of DEB and thin-DES in DES-ISR.

De Filippo O, Wańha W, Sanavia T, Januszek R, Giacobbe F, Campo G, Pinxterhuis TH, Capodanno D, Tomasiewicz B, Iannaccone M, Leone A, Wolny R, Bruno F, Patti G, Musumeci G, Liccardo G, Verardi R, Roubin SR, Tarantini G, Kuźma Ł, Perl L, Gagnor A, Reczuch K, Conrotto F, Tuttolomondo D, Ploumen EH, Niezgoda P, Caglioni S, Omedè P, Greco A, Kubica J, Gil RJ, Piccolo R, Kornowski R, Bil J, Morena A, Zocca P, Pennone M, Gąsior M, Jaguszewski M, von Birgelen C, Fariselli P, De Ferrari GM, Wojakowski W, D'Ascenzo F.

2024-11-043 citations

10.4244/eij-d-24-00491

Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry)

Wojciech Wańha, Jacek Bil, Rafał Januszek, Natasza Gilis‐Malinowska, Tomasz Figatowski et al. (39 authors)

Circulation Cardiovascular Interventions2021-09-0128 citations

10.1161/circinterventions.121.010868

Interventions

DEVICEpercutaneous coronary intervention

Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Inclusion criteria

• All consecutive patients with DES-ISR who were treated with either paclitaxel-DEB or thin-DES.

Exclusion criteria

* PCI with DES struts thickness \>100μm * PCI with DEB and thin-DES in the same procedure * PCI of other vascular territories during the same procedure * PCI in saphenous vain graft or internal mammary artery

Design outcomes

Primary

Measure	Time frame	Description
TLR	3 years	target lesion revascularisation

Secondary

Measure	Time frame	Description
DOCE	3 years	composite of cardiac death, TLR, and target vessel MI
TVR	3 years	target vessel revascularization
TV-MI	3 years	target vessel myocardial infarction
cardiac death	3 years	—
myocardial infarction	3 years	—

Countries

Poland

Outcome results

None listed